Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab and Tracon Begin US Trials of CD73 Antibody

publication date: Aug 1, 2019

I-Mab Biopharma, a Shanghai-San Diego biopharma, announced its US partner, Tracon Pharma, has begun a US Phase I clinical trial of I-Mab's CD73 antibody in patients with advanced solid tumors. TJD5 is a novel antibody that blocks CD73, a highly immunosuppressive surface enzyme on cancer cells. In the first-in-human trial, TJD5 will be dosed as a single agent and in combination with Tecentriq®, a Roche PD-L1 antibody. I-Mab intends to start similar China trials of TJD5 as well. More details....

Stock Symbol: (NSDQ: TCON)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.